Sapienza University, Sant'Andrea Hospital, Advanced Molecular Diagnostic Unit, NESMOS Department, Rome, Italy.
Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1043-50. doi: 10.1517/17425255.2012.701618. Epub 2012 Jul 5.
Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction. The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies. Acute treatments consist of triptan, ergot, opioid, antiemetic and NSAIDs.
This article discusses pharmacodynamics and pharmacokinetics of zolmitriptan . The data were obtained by searching the following keywords in MEDLINE: zolmitriptan, pharmacokinetics, pharmacodynamics, triptans, migraine, menstrual-related migraine, cluster headache, relatively to the period 1989 - 2012.
Zolmitriptan has been considered effective treatment in the acute phase of migraine, menstrual-related migraine and cluster headache attacks. Pharmacokinetic parameters may vary as a consequence of gender differences, inter- and intra-subjects variability and delivery system. Zolmitriptan was developed with the aim of obtaining a lipophilic compound in order to be more rapidly absorbed and centrally active. Pharmacologically, pharmacokinetic parameters are responsible for its wide efficacy and the limited adverse effect profile.
偏头痛是一种多因素的神经血管性疾病，其特征是反复发作的致残性疼痛发作，并伴有胃肠道、神经系统功能障碍。偏头痛的药物治疗传统上分为急性发作的治疗和预防策略。急性治疗包括曲坦类、麦角类、阿片类、止吐药和 NSAIDs。
本文讨论了佐米曲普坦的药效学和药代动力学。数据是通过在 MEDLINE 中搜索以下关键词获得的：佐米曲普坦、药代动力学、药效学、曲坦类、偏头痛、与月经相关的偏头痛、丛集性头痛，时间范围为 1989 年至 2012 年。
佐米曲普坦被认为是偏头痛、与月经相关的偏头痛和丛集性头痛发作急性期的有效治疗药物。药代动力学参数可能因性别差异、个体间和个体内变异性以及给药系统而有所不同。佐米曲普坦的开发目的是获得一种亲脂性化合物，以便更快速地吸收并具有中枢活性。在药理学上，药代动力学参数决定了其广泛的疗效和有限的不良反应谱。
